PROCEPT BioRobotics Corporation (PRCT) Stock Analysis
A live, multi-source view of PROCEPT BioRobotics Corporation (PRCT): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Sector: Healthcare · Industry: Medical Devices · United States · 888 employees · procept-biorobotics.com
Key statistics · as of 2026-09-05
As of 2026-09-05, PROCEPT BioRobotics Corporation (PRCT) had a market capitalization of $1.30B (forward -19.7) and a beta of 0.90; the shares traded in a 52-week range of $16.66 – $41.51 (-41.5% over the year).
- Market cap
- $1.30B
- Enterprise value
- $1.15B
- Forward P/E
- -19.7
- Price / book
- 3.83
- EPS (trailing)
- $-2.08
- EPS (forward)
- $-1.15
- Payout ratio
- 0.0%
- 52-week range
- $16.66 – $41.51
- 52-week change
- -41.5%
- Beta
- 0.90
- Average volume
- 1.6M
- Shares outstanding
- 56.9M
- Short % of float
- 13.84%
- Profit margin
- -32.5%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, PROCEPT BioRobotics Corporation (PRCT) last closed at $20.07 (the last completed close before that scan).
Technicals at the scan: RSI 45 (neutral territory), price -5.8% versus its 20-day average, 20-day versus 50-day average spread +5.1%, MACD histogram -0.12.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 55/100.
Next scheduled company event: in 54 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of PRCT; corporate insiders filed 1 buy and 3 sells (4 distinct filers, latest disclosure 2026-09-10). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Barry L. Templin (0B/1S), Alaleh Nouri (0B/1S), Kevin Waters (0B/1S), Larry L. Wood (1B/0S). Who is trading what
RapidTradeView pick record
PRCT has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls PROCEPT BioRobotics Corporation (PRCT) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell PRCT.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.